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METHOD OF USING CCR3 BINDING 
AGENTS TO DETECT CHOROIDAL 
NEOVASCULARIZATION 
This application is a national stage of PCT International 
Application No. PCT/US2010/036202, ?led May 26, 2010, 
which claims priority under 35 U.S.C. 119(e) to provisional 
application No. 61/181,161, ?led May 26, 2009. 
BACKGROUND 
Age-related macular degeneration (AMD), a leading cause 
of blindness worldwide, is as prevalent as cancer in industri 
alized nations. Most blindness in AMD results from invasion 
of the retina by choroidal neovascularization (CNV). AMD 
affects 30-50 million people globally, with approximately 
90% of severe vision loss attributed to CNV (Ambati, 1., et al., 
Surv Ophthalmol. 48, 257-293 (2003)). The worldwide 
prevalence of CNV is expected to double in the next decade 
due to population aging. Targeting the pro-angiogenic cytok 
ine vascular endothelial growth factor (V EGF)-A has been 
validated in patients with CNV (Gragoudas, et al. N Engl J. 
Med. 351, 2805-2816 (2004); Brown. et al. NEngl J. Med. 
355, 1432-1444 (2006); Rosenfeld, et al. NEnglJ. Med. 355, 
1419-1431 (2006)). However, substantial improvement of 
vision occurs only in one-third of patients treated with 
VEGF-A antagonists, and one-sixth of treated patients still 
progress to legal blindness. Moreover, safety concerns with 
continual (Brown, et al. N Engl J. Med. 355, 1432-1444 
(2006)) blockade of VEGF-A, which is constitutively 
expressed in the normal adult human retina Famiglietti et al. 
Brain Res. 969, 195-204 (2003)), are emerging Nishijima et 
al., Am J Pathol. 171, 53-67 (2007); Saint-Geniez et al., PLoS 
ONE. 3, e3554 (2008)). Thus, treatment strategies based on 
more speci?c targeting of CNV are desirable. However, no 
molecular marker speci?c for human CNV has yet been 
reported. 
BRIEF DESCRIPTION OF THE FIGURES 
FIGS. la-j show that CCR3 and eotaxins are expressed in 
choroidal neovascularization. (a,b) Immuno?uorescence 
shows that CCR3 receptor expression colocalizes with 
CD31+ expressing blood vessels in surgically excised human 
AMD CNV tissue. Nuclei stained blue by DAPI. (b) Speci 
?city of CCR3 staining is con?rmed by absence of staining 
with isotype control IgG (a). (c,d) CCR3 is not immunolo 
calized in CD31+ blood vessels (white arrowheads) in the 
choroid of patients with atrophic AMD who do not have CNV 
(c) or in aged patients without AMD (d). Auto?uorescence of 
retinal pigmented epithelium (white arrow) and Bruch’s 
membrane (asterisks) overlying choroid is seen (c,d). (e,f) 
CCR3 is not expressed in surgically excised avascular retinal 
?brosis tissue (e) or in blood vessel of choroidal melanoma 
(f). (g-j) Immunohistochemistry shows expression of CCL11 
(g), CCL24 (h), and CCL26 (i) in surgically excised AMD 
CNV tissue, primarily in the stroma (arrowheads) but also in 
the blood vessels (arrows). Speci?city of staining is con 
?rmed by absence of staining with isotype control IgG (j). 
Scale bars, 10 um. 
FIGS. 2a-f show CCR3 activation promotes angiogenesis. 
(a) Tube formation of primary human choroidal endothelial 
cells (CECs) in Matrigel in vitro was reduced by neutralizing 
anti-human CCR3 antibodies (Ab) compared to isotype IgG. 
n:6, *P<0.05 compared to isotype IgG. (b) Fraction of 
CD31+VEGFR2+ gated mouse CECs in vivo in proliferative 
state (S phase) was increased 5 days after laser injury in 
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wild-type mouse eyes compared to control (uninjured eyes), 
and was reduced by intraocular administration of neutralizing 
anti-mouse CCR3Ab compared to isotype IgG. n:6-10, 
*P<0.05 compared to IgG treatment. (c) Stimulation with 
eotaxins for 24 h induced human CEC proliferation. n:4, 
*P<0.05 compared to bovine serum albumin (BSA) treat 
ment. (d,e) Stimulation with eotaxins, but not PBS, induced 
actin polymerization in human CECs. Relative F-actin con 
tent is expressed as the ratio of the mean channel ?uorescence 
between eotaxin- and media alone-stimulated cells (d). 
Rhodamine-phalloidin staining shows F-actin ?bre formation 
in eotaxin-stimulated cells (e). Nuclei stained blue by DAPI. 
Data representative of 3-4 independent experiments are 
shown. (c,e) CCL11 (10 ng/ml), CCL24 (100 ng/ml), CCL26 
(2 ug/ml). (f) Stimulation with eotaxins for 16 hours induces 
dose-dependent migration of human CECs across 8 pm pore 
size Transwells. n:5-10, *P<0.05 compared to BSA treat 
ment. (a-c, f) Signi?cance by Mann-Whitney U test. Error 
bars depict s.e.m. 
FIGS. 3a-j show that CNV is reduced by CCR3 or eotaxin 
ablation or blockade independent of leukocyte modulation. 
(a,b) Laser-induced CNV in wild-type mice was reduced by 
neutralizing anti-mouse CCR3Ab compared to isotype IgG 
(a) and by the CCR3 receptor antagonist (RA) SB328437 
((S)-Methyl-2-naphthoylamino-3-(4-nitrophenyl)propi 
onate) compared to vehicle (PBS/DMSO) (b) in a dose-de 
pendent fashion. n:8-12, *P<0.05 compared to no antibody 
or receptor antagonist. (c) Representative examples of CNV 
in drug-treated mice. (d) Laser-induced CNV was reduced in 
CCR3_/_ mice compared to wild-type mice. n:9, *P<0.05 
compared to wild-type mice. (e) Eotaxin-1 (Ccl-11) and 
eotaxin-2 (Ccl-24) protein levels, measured by ELISA, were 
increased following laser injury in wild-type mice. n:6, 
*P<0.05, #P<0.01 compared to 0 h baseline. (f) CCL-11 and 
CCL-24 immuno?uorescence was localized in the retinal 
pigmented epithelial cell layer (arrows) adjacent to CD31+ 
choroidal endothelial cells (arrowheads) on day 1 after laser 
injury in wild-type mice. Nuclei stained blue by DAPI. No 
speci?c immuno?uorescence was detected with isotype con 
trol IgGs. Images representative of 3 independent experi 
ments are shown. (g) Laser-induced CNV was reduced in 
CCL11_/_ and in CCL24_/_ mice compared to wild-type 
mice. n:8-10, *P<0.05 compared to wild-type mice. CNV is 
further reduced in CCL 11_/_><CCL24_/_ mice compared to 
single null mice. #P<0.05 compared to single null mice. (h) 
Laser-induced CNV in wild-type mice was reduced by neu 
tralizing antibodies against mouse CCL11 or CCL24 com 
pared to isotype IgG. n:7-10, *P<0.05 compared to no injec 
tion (control) or IgG. (i) Representative examples of CNV in 
eotaxin-neutralized mice. (j) Neutralizing anti-CCR3 anti 
bodies (Ab) reduced laser-induced CNV in mice de?cient in 
eosinophils (Adbl GATA) or mast cells (Kitw'v). n:6-9, 
*P<0.05 compared to IgG. Scale bars, (c,i), 100 um; f, 20 um. 
Error bars depict s.e.m. 
FIGS. 4a-g demonstrate that CCR3-targeting quantum 
dots detect subretinal choroidal neovascularization (CNV). 
(a) Images of the fundus taken after intravenous injection of 
sodium ?uorescein in wild-type and CCL2_/_><CCRT_/_ mice 
showed normal retinal vascular ?lling, but no areas of hyper 
?uorescence indicative of CNV. (b) After intravenous injec 
tion of QDot-CCR3 Fab in the same CCL2_/_><CCR2_/_ 
mouse shown in (a), focal branching choroidal hyper?uores 
cence was visualized (arrow) at 1 h in the same area that was 
not hyper?uorescent during ?uorescein angiography (arrow 
head in a). The intensity of this hyper?uorescence (shown in 
the inset) increased, attaining a peak at 4 h, and then declined 
in intensity but still persisted at 12 h. Corresponding images 
US 8,778,616 B2 
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of QDot-Isotype Fab angiography showed no hyper?uores 
cence. (c-e) The region corresponding to the area of hyper 
?uorescence seen on QDot-CCR3Fab angiography in (b) 
contained multiple CD31+ blood vessels in the choroid (Ch) 
that were proliferating (Ki67+; arrows) and had not invaded 
the retina (Ret). Individual CD31+ (c), and Ki67+ (d), and 
merged (e) ?uorescence channel images are shown. Arrows 
point to proliferating endothelial cells. Inset shows Ki67+ 
CD31+ cells in higher magni?cation. (f) QDot-CCR3Fab 
hyper?uorescent areas were localized to areas of subretinal 
CNV with CCR3+ endothelial cells. (g) The QDot label was 
visualized within CD31+ vasculature of subretinal CNV 
lesions. Images representative of 6 independent experiments. 
Scale bars, (c-e), 10 pm. 
FIG. 5 shows that eotaxins activate Rac-1. Stimulation of 
human CECs with CCL11 (10 ng/ml), CCL24 (100 ng/ml), or 
CCL26 (2 pg/ml) increased levels of activate Rac-1 GTPase 
in human CECs compared to unstimulated (0 s) cells. Equal 
amounts (500 pg) of total cell lysates were probed for GTP 
bound Rac-1 (active) by pull-down assays. Rac-1 and 
GAPDH immunoblotting were also performed using equal 
amounts (80 pg) of the original lysates to control for protein 
loading. Representative images of 3 independent experiments 
are shown. 
FIG. 6 shows that CCL11, CCL24, and CCL26 mRNA are 
expressed in cultured human RPE cells. Total RNA isolated 
from human RPE cells were subjected to RT-QPCR using 
speci?c primers for the three eotaxins or ribosomal 18S as 
control. Only one band with the predicted size was observed 
for each gene, and not in the corresponding negative control 
(H20). 
FIGS. 7a-c show that CCR3 does not promote in?amma 
tion in mouse CNV model. (a) Laser injury did not recruit 
eosinophils (CCR3hiCD3_CD117i”’CD49d+) or mast cells 
(CCR3i”’CD3_CD117hiCD49d+) into the choroid. 11:8. (b,c) 
Neutralizing anti-CCR3 Ab did not reduce in?ltration of mac 
rophages (Gr-1+F4/80_) 3 days after (b) or of neutrophils 
(F4/80+CD11c_) 1 day after (c) into the choroid following 
laser injury in wild-type mice. n:6. Macrophage and neutro 
phil index refer to the fraction of choroidal cells comprised of 
these in?ammatory cells, normalized to value in PBS-treated 
eyes, at the peak of their in?ltration (3 days for macrophages 
and 1 day for neutrophils). 
FIG. 8 shows that CCR3 F(ab) Ab fragment detects CCR3 
speci?cally. Thioglycolate-elicited cells obtained from wild 
type (WT) and Ccr3 —/— mice were subjected to FACS analy 
sis. SSChigh cells were electronically gated and assessed for 
SiglecF and CCR3 expression using the indicated antibodies. 
Eosinophil percentage (CCR3+/SiglecF+) is depicted in 
upper right corner of the dot-plot graph. Data are a represen 
tative experiment of n:4-6 mice per group. SSC, side scatter. 
SiglecF (Sialic acid-binding immunoglobulin-like lectin-F) 
is an eosinophil-prominent Siglec. SSCiH and FSH4C 
show the cell size and granularity and FLl-H and FL2-H 
show the staining intensity of the different antibodies used to 
stain cells. 
FIG. 9 shows that CCR3 blockade is more effective at 
inhibiting CNV than VEGF-A blockade. A dose-ranging (0.5 
ng-1 pg) study determined that the optimal dose of anti 
VEGF-A neutralizing antibody (Ab) for inhibiting laser-in 
duced CNV in wild-type mice when administered into the 
vitreous humor was 2 ng. The peak of CNV inhibition by 
VEGF-A neutralization was 57:4% compared to isotype 
control IgG, whereas anti-CCR3 neutralizing Ab, at an opti 
mal dose of 1 pg, achieved an inhibition of 68:3% (BP<0.05) 
compared to isotype control IgG. n:20—25. 
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FIGS. 1011-!) show that CCR3 and VEGF-A do not modu 
late each other. (a) Intravitreous administration of anti-CCR3 
neutralizing antibody (1 pg) following laser injury in wild 
type mice did not change VEGF-A levels in the RPE/ choroid 
3 days after injury, compared to isotype control IgG (1 pg) 
administration. n:4. (b) Intravitreous administration of anti 
VEGF-A neutralizing antibody (2 ng; gray curve) following 
laser injury in wild-type mice did not change surface CCR3 
expression on CD31+VEGFR-2+ choroidal endothelial cells 
5 days after injury compared to isotype control IgG (2 ng; 
black curve) administration. SFI, standardized ?uorescence 
index (ratio of geometric means of cells exposed to control 
IgG (black curve) to cells exposed to anti-VEGF-A antibody 
(gray curve), n:3. 
DESCRIPTION OF THE INVENTION 
CCR3 Expression Restricted to CNV in Human Eyes 
In our studies examining the role of chemokines in angio 
genesis, we discovered that CCR3 (also known as CD193), a 
chemokine receptor best known for its role in promoting 
eosinophil and mast cell traf?cking (Rothenberg and Hogan 
Annu Rev Immunol. 24, 147-174 (2006)), was expressed in 
human choroidal endothelial cells (CECs) only in the context 
of CNV due to AMD and not in other non-proliferating or 
proliferating choroidal vasculature (FIG. 1). Immunolocal 
ization studies showed that CCR3 was expressed in CECs of 
all examined specimens of surgically excised CNV tissue 
from patients with AMD (18/ 18) who had received no prior 
treatment for AMD (FIG. 1a, b). In contrast, CCR3 was not 
expressed in CECs in the choroid of any patients with early 
(atrophic) AMD (0/ 10) or in age-matched patients without 
AMD (0/ 10) (FIG. lc, d). CCR3 also was not immunolocal 
ized in surgically excised tissue from patients with epiretinal 
?brotic membranes (0/ 6) or in CECs in patients with choroi 
dal melanoma (0/ 8) (FIG. 1e, f). Collectively these data point 
to a highly speci?c pattern of expression of CCR3 
(P:7><10_l4, exact contingency table test) in CECs in neovas 
cular AMD. In addition, we identi?ed the expression of the 
CCR3 ligands eotaxin-1 (CCL11), -2 (CCL24), and -3 
(CCL26) in all examined specimens of surgically excised 
CNV tissue from patients with AMD who had received no 
prior treatment for AMD (FIG. 1g-j), suggesting that the 
eotaxin-CCR3 axis could play a role in this disease state. 
Interestingly, despite the abundance of eotaxins, eosinophils 
and mast cells were not identi?ed in human CNV, consistent 
with earlier ?ndings Grossniklaus et al. Arch Ophthalmol. 
123, 914-921 (2005). 
CCR3 Stimulation Promotes CEC Migration and Prolif 
eration 
The best elucidated pathological functions of CCR3 to date 
have been its role in allergic diseases such as asthma (Justice 
et al., Am JPhysiol Lung Cell Mol. Physiol. 284, L169-178 
(2003); Humbles. et al., Science. 305, 1776-1779 (2004); 
Pope et al., J. Immunol. 175, 5341-5350 (2005); Jose et al., J 
Exp Med. 179, 881-887 (1994); Teixeira et al., J Clin Invest. 
100, 1657-1666 (1997)) and eosinophilic esophagitis (Blan 
chard et al., J Clin Invest. 116, 536-547 (2006). There is a 
single report of its direct role in angiogenesis Salcedo et al., J. 
Immunol. 166, 7571 -7578 (2001)). Although eosinophils and 
mast cells have been reported to be involved in angiogenesis 
(Puxeddu et al., InZJBiochem Cell Biol. 37, 628-636 (2005); 
Heissig et al., J Exp Med. 202, 739-750 (2005)), such actions 
are considered minor or isolated. Therefore, we studied the 
effects of CCR3 modulation on angiogenesis in vitro and in 
VlVO. 
Neutralizing anti-CCR3 antibodies inhibited the tube for 
mation of primary human CECs cultured in Matrigel in vitro 
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(FIG. 2a). In an experimental model of CNV induced by laser 
injury in wild-type mice (Tobe et al., Am J. Pathol. 153, 
1641-1646 (1998); Nozaki et al. Proc Natl Acad Sci USA. 
103, 2328-2333 (2006); Nozaki et al., J Clin Invest. 116, 
422-429 (2006); Kleinman et al., Nature. 452, 591-597 
(2008); Sakurai et al., Invest Ophthalmol Vis Sci. 44, 3578 
3585 (2003); Sakurai et al. Invest Ophthalmol Vis Sci. 44, 
2743-2749 (2003)), neutralizing anti-CCR3 antibodies 
reduced the fraction of CECs in vivo that were in the prolif 
erative state of the cell cycle (FIG. 2b). Consistent with this 
?nding, each of the three eotaxins stimulated human CEC 
proliferation (FIG. 2c). Cytoskeletal rearrangement through 
polymerization of monomeric actin to micro?lamentous 
F-actin, which is essential for eosinophil chemotaxis induced 
by the eotaxins, is also critical in angiogenic migration of 
endothelial cells. Stimulation of human CECs with any of the 
three eotaxins induced a rapid polymerization of actin mol 
ecules (FIG. 2d e). All three eotaxins also activated Rac-l 
(FIG. 5), a small GTPase that is critical in regulating endot 
helial cell spreading and migration, and promoted human 
CEC migration in a dose-dependent fashion (FIG. 2]). Col 
lectively these data demonstrate that CCR3 activation can 
promote multiple steps of angiogenesis. The expression of 
CCR3 on CECs in vivo is con?ned to CNV tissues; however, 
in vitro, human CECs responded to CCR3 ligands. Without 
wishing to be bound by theory, this might be due to the 
presence of several CNV-promoting growth factors in the 
culture medium. 
CCR3 Receptor or Ligand Antagonism Inhibits CNV 
We studied the in vivo effects of CCR3 targeting in a mouse 
model of CNV induced by laser injury (Kleinman et al., 
Nature. 452, 591-597 (2008)), which is the most widely uti 
lized animal model of this disease. A single intraocular 
administration of either CCR3 neutralizing antibodies or a 
small molecule CCR3 receptor antagonist ((S)-Methyl-2 
naphthoylamino-3-(4-nitrophenyl)propionate) both sup 
pressed laser injury-induced CNV in wild-type mice in a 
dose-dependent fashion (FIG. 3a-c). CNV was also dimin 
ished in Ccr3_/_ mice (Humbles et al., Proc Natl Acad Sci 
USA. 99, 1479-1484 (2002)) as compared to wild-type mice 
(FIG. 3d). The speci?city of pharmacological CCR3 block 
ade was con?rmed by demonstrating that CNV was not 
reduced in Ccr3_/_ mice by CCR3 neutralizing antibodies or 
CCR3 receptor antagonist (1 16:7% and 109116% of control, 
respectively; n:5; P>0.1). CCL-l 1 and CCL-24, the principal 
mouse ligands for CCR3, were markedly increased soon after 
laser injury and immunolocalized to the retinal pigmented 
epithelium (RPE), which is adjacent to CECs (FIG. 3e, j). 
Also, human RPE cells synthesized all three eotaxins (FIG. 
6), implicating these cells, which are abundantly interspersed 
in CNV (Grossniklaus et al. Arch Ophthalmol. 123, 914-921 
(2005)), as a source of CCR3 ligands in CNV. Genetic abla 
tion of either Cc111 (Rothenberg, et al., J Exp Med. 185, 
785-790 (1997)) or Ccl24 (Pope et al., J Immunol. 175, 
5341-5350 (2005) reduced CNV, while the neovascular 
response in Cc111_/_><Ccl24_/_ mice (Pope et al. (2005) 
supra) was suppressed to a greater extent than in either of the 
“single knockout” mice, suggesting cooperation between 
these two ligands in this system (FIG. 3g). A single intraocu 
lar administration of neutralizing antibodies against CCL-ll 
or CCL-24 also suppressed CNV in wild-type mice (FIG. 3h, 
i), validating these CCR3 ligands as anti-angiogenic targets. 
Together, these data demonstrate that CCR3 activation is 
essential for in vivo angiogenesis in the most widely used 
preclinical model of neovascular AMD. 
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CCR3-Driven Angiogenesis Uncoupled from In?amma 
tion 
We sought to determine whether CCR3 targeting reduced 
CNV solely via anti-angiogenic mechanisms or whether anti 
in?ammatory mechanisms also were involved. Neither eosi 
nophils nor mast cells (de?ned as CCR3hiCD3_ 
CD117””CD49d+ and CCR3””CD3_CD117hiCD49d+ cells, 
respectively) were recruited to the choroid following laser 
injury, as monitored by ?ow cytometry (FIG. 7). Further 
more, the CNV response in eosinophil-de?cient Adbl GATA 
mice (Humbles et al., Science. 305, 1776-1779 (2004) and 
mast cell-de?cient KitW'vv/KitW'” mice (Kitamura et al., 
Blood. 52, 447-452 (1978) was not different from that in 
wild-type mice (FIG. 3 j). In addition, intraocular administra 
tion of neutralizing anti-CCR3 antibodies reduced CNV in 
Adbl GATA or KitW'v/KitW'“ mice to the same extent as in 
wild-type mice. Thus, although eosinophils and mast cells 
have been reported to be capable of driving angiogenesis in 
other systems (Puxeddu et al., Int J Biochem Cell Biol. 37, 
628-636 (2005); Heissig et al., J Exp Med. 202, 739-750 
(2005), both cell types are dispensable in the development of 
experimental CNV. Although neutrophil and macrophage 
in?ltration are crucial for the development of experimental 
CNV (Sakurai et al. (2003) supra; Zhou et al. Mol. Vis. 11, 
414-424 (2005), CCR3 receptor targeting did not affect 
recruitment of either in?ammatory cell type (de?ned as Gr-1+ 
F4/80' and F4/80+CD11c_ cells, respectively) (FIG. 7). 
Therefore, the angioinhibitory effect of CCR3 blockade in 
this model is a direct anti-vascular effect and does not appear 
to involve modulation of cellular in?ammation. The mecha 
nisms underlying the paucity of eosinophils and mast cells in 
CNV remain to be de?ned. While not wishing to be bound by 
theory, one explanation could be the expression of CXCL9, 
which blocks eotaxin-induced CCR3-mediated eosinophil 
recruitment (Fulkerson et al., Proc Natl Acad Sci USA. 101, 
1987-1992 (2004); Fulkerson et al. Blood. 106, 436-443 
(2005) in CNV. Other mechanisms in?uencing adhesion or 
mobilization of these leukocytes also might be operative. 
CNV Bioimaging by Ccr3 Targeting 
Because invasion of the retina by CNV results in morpho 
logical and functional disruption of the retina, early detection 
of CNV is desirable; indeed, detection of CNV before retinal 
invasion would be ideal. CNV that has breached the retina can 
be detected by ?uorescein angiography. However, this diag 
nostic modality cannot detect CNV before it has invaded the 
retina, i.e., when it is still limited to the choroid. Yet postmor 
tem histopathological studies have shown that substantial 
numbers of patients in whom ?uorescein angiography does 
not reveal the presence of CNV nevertheless have CNV that 
has not yet invaded the retina (Green and Key, Trans Am 
Ophthalmol Soc. 75, 180-254 (1977). Therefore, we explored 
whether CCR3-targeted bioimaging using anti-CCR3 Fab 
antibody fragments (FIG. 8) conjugated to quantum dots 
(QDot-CCR3 Fab) could detect CNV before it became clini 
cally evident. 
We previously described the spontaneous development of 
CNV in senescent mice de?cient in monocyte chemoattrac 
tant protein-1 (MCP-l/CCL-2) or its CCR2 receptor (Ambati 
et al., Nat. Med. 9, 1390-1397 (2003)). Similar pathology 
occurs at a younger age in Ccl2_/_><Ccr2_/_ mice (unpub 
lished data). These mice also undergo outer retinal degenera 
tion rapidly. We tested whether fundus angiography follow 
ing intravenous injection of QDot-CCR3 Fab could detect 
subretinal CNV in these mice. QDot-CCR3 Fab angiography 
demonstrated hyper?uorescent signals in regions of the fun 
dus of these mice that were silent on ?uorescein angiography 
(FIG. 4a, b). The speci?city of CCR3 targeting was con?rmed 
US 8,778,616 B2 
7 
by the absence of hyper?uorescent signals in Ccl2_/_>< 
Ccr2_/_ mice injected with QDot-isotype Fab and in wild 
type mice injected with QDot-CCR3 Fab (FIG. 4b). Histo 
logical examination of these areas revealed proliferating 
(Ki67+) CCR3+ blood vessels in the choroid that had not yet 
invaded the retina, along with accumulation of QDot-CCR3 
Fab in these vessels (FIG. 4c-e). These data demonstrate that 
CCR3-targeted bioimaging can detect subclinical CNV 
before it disrupts the retina and causes vision loss. 
CCR3 Targeting Superior to VEGF-A Targeting 
In comparing CCR3 targeting to VEGF-A targeting, the 
mo st effective approved treatment for human CNV, we found 
that CCR3 neutraliZing antibodies were more effective than 
VEGF-A neutraliZing antibodies (68:3% vs. 57:4%) at 
inhibiting laser-induced CNV in mice (FIG. 9). In the laser 
injury model, CCR3 neutralization did not change VEGF-A 
levels in the RPE/choroid and VEGF-A blockade did not 
change CCR3 expression on CECs (FIG. 10): these two path 
ways appear to be not directly coupled. Repeated intravitre 
ous administration of anti-VEGF-A antibodies resulted in 
anatomic and functional damage to the retina in wild-type 
mice, consistent with earlier reports that anti-VEGF-A 
therapy induces dysfunction in and damage to the inner and 
outer murine retina6’7. These effects were modest at a dose of 
anti-VEGF-A antibodies that suppressed mouse CNV but 
more pronounced at a higher dose that is comparable to the 
dose used in humans. It should be noted that anti-VEGF-A 
pharmacotherapy has not been associated with an increased 
risk of profound retinal damage in humans (Ip et al., Ophthal 
mology. 115, 1837-1846 (2008), but subtle abnormalities 
have been observed (Sayanagi et al., Br]. Ophthalmol. Feb 
ruary 10 [Epub ahead of print] (2009); Yodoi et al. Am J. 
Ophthalmol. 147, 816-824 (2009)) and some adverse effects 
might be misattributed to disease progression. In contrast to 
VEGF-A blockade, neither CCR3 Ab nor CCR3 receptor 
antagonist induced retinal toxicity in wild-type mice as con 
?rmed by fundus imaging and electrophysiological function. 
Vegfa deletion is embryonically lethal (Carmeliet et al., 
Nature. 380, 435-439 (1996); Ferrara et al., Nature. 380, 
439-442 (1996)) and conditional ablation of Vegfa in the RPE 
induces profound retinal degeneration and visual dysfunction 
(Marneros et al., Am J. Pathol. 167, 1451-1459 (2005). In 
contrast, the Ccr3_/_ mouse retina was normal in appearance 
and electrophysiological function. 
Discussion 
CCR3 targeting is useful for early detection (using bio 
compatible quantum dots or other bioimaging ?uorochromes 
such as near infrared dyes) and treatment of CNV (by receptor 
or ligand targeting) superior to current standard of care. 
CCR3 bioimaging is useful in individuals with RPE pigmen 
tary disturbances and multiple subretinal lipoproteinaceous 
deposits known as drusen or fellow eye involvement with 
clinically evident CNV, as they are known to be at high risk 
for developing CNV (Bressler et al., Arch Ophthalmol. 108, 
1442-1447 (1990); Maguire et al. Arch Ophthalmol. 115, 
741-747 (1997). Similar techniques are also useful in non 
invasively bioimaging other metabolic or molecular markers 
to provide information about disease pathogenesis or activity. 
For example, metabolic or molecular markers in tissues of the 
eye can be detected by contacting the tissue with an agent 
speci?c for that metabolic or molecular marker wherein the 
agent is labeled with a NIRF or Qdot and the label is detected 
by using angiography techniques that are well-known in the 
art. 
Several strategies have yielded molecular markers that are 
preferentially expressed on proliferating endothelial cells 
such as those in tumor vasculature (St Croix et al., Science 
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289, 1197-1202 (2000); Zhang et al., Science 276, 1268-1272 
(1 997)) however, CCR3 has not been identi?ed in any of these 
reports. Therefore, our studies identify CCR3 as a novel 
marker of pathological angiogenesis and as a functional target 
in neovascular AMD. 
Thus, an aspect of this invention is a method for detecting 
subclinical CNV comprising contacting the choroid of a sub 
ject with an agent that speci?cally binds to CCR3 or to 
eotaxin 1, 2 or 3, and then assaying the choroid for binding of 
the agent to vessels in the choriod, wherein binding of the 
agent to vessels in the choroid is indicative of subclinical 
CNV. Subclinical as used herein refers to subjects who do 
have CNV invasion of the retina. Agents that speci?cally bind 
to CCR3 or to eotaxin 1, 2 or 3 include, e.g., CCR3- or 
eotaxin-speci?c antibody or antibody fragments, eotaxins 1, 
2, or 3 and fragments of eotaxin 1, 2 or 3 that bind to CCR3; 
or peptides or aptamers that speci?cally bind to CCR3 or 
eotaxin 1, 2 or 3; or a CCR3-speci?c small molecule inhibitor, 
see for example US. Publication No. 20070190055 for a 
description of numerous small molecule inhibitors for the 
CCR3 receptor have been developed and can be used in the 
present invention. See also US. Pat. Nos. 6,806,061 and 
6,207,155, and in US. published applications 20050191702, 
20050069955, and 20020147312 for exemplary antibodies 
which speci?cally bind and inhibit the CCR3 receptor and 
US. Pat. Nos. 6,946,546 and 6,635,251, and in US. pub 
lished applications 20040191255 and 20040014132 for 
exemplary antibodies, which speci?cally bind and inhibit 
eotaxin and eotaxin-2. 
Antibodies and antibody fragments speci?c for CCR3 or 
eotaxins can be generated using any number of techniques 
well-known in the art. For example, for preparation of mono 
clonal antibodies, any technique which provides for the pro 
duction of antibody molecules by continuous cell lines in 
culture may be used. For example, the hybridoma technique 
originally developed by Kohler and Milstein (Nature 256: 
495-497 (1975)), as well as the trioma technique, the human 
B-cell hybridoma technique (Kozbor et al., Immunology 
Today 4:72 (1983)), and the EBV-hybridoma technique to 
produce human monoclonal antibodies (Cole et al., in 
“Monoclonal Antibodies and Cancer Therapy,” Alan R. Liss, 
Inc. pp. 77-96 (1985)) and the like are within the scope of the 
present invention. 
The monoclonal antibodies for therapeutic use may be 
human monoclonal antibodies or e.g., chimeric human 
mouse (or other species) monoclonal antibodies. Human 
monoclonal antibodies may be made by any of numerous 
techniques known in the art (e.g., Teng et al., (1983) Proc. 
Natl. Acad. Sci. USA. 80:7308-7312; KoZbor et al., (1983) 
Immunology Today 4:72-79; Olsson et al., (1982) Meth. Enzy 
mol. 9213-16). Chimeric antibody molecules may be prepared 
containing a mouse antigen-binding domain with human con 
stant regions (Morrison et al., (1984) Proc. Natl. Acad. Sci. 
USA. 8116851, Takeda et al., (1985) Nature 314:452). Vari 
ous procedures known in the art may be used for the produc 
tion of polyclonal antibodies to epitopes of CCR3. For the 
production of antibody, various host animals can be immu 
nized by injection with CCR3 protein, or fragment or deriva 
tive thereof, including but not limited to rabbits, mice, rats, 
etc. A molecular clone of an antibody to a CCR3 epitope can 
be prepared by known techniques. Recombinant DNA meth 
odology (see e.g., Maniatis et al., 1982, Molecular Cloning,A 
Laboratory Manual, Cold Spring Harbor Laboratory, Cold 
Spring Harbor, NY.) may be used to construct nucleic acid 
sequences which encode a monoclonal antibody molecule, or 
antigen binding region thereof. such fragments include but 
are not limited to: the F(ab')2 fragment which can be produced 
US 8,778,616 B2 
by pepsin digestion of the antibody molecule; the Fab' frag 
ments which can be generated by reducing the disul?de 
bridges of the F(ab')2 fragment, and the Fab fragments which 
can be generated by treating the antibody molecule with 
papain and a reducing agent. See also, e.g., Cabilly et al., U.S. 
Pat. No. 4,816,567; Cabilly et al., European Patent No. 0, 125, 
023. B1; Boss et al., U.S. Pat. No. 4,816,397; Boss et al., 
European Patent No. 0,120,694 B1; Neuberger, M. S. et al., 
WO 86/01533; Neuberger, M. S. et al., European Patent No. 
0,194,276 B1; Winter, U.S. Pat. No. 5,225,539; and Winter, 
European Patent No. 0,239,400 B1. See also, Newman, R. et 
al., BioTechnology, 10: 1455-1460 (1992), regarding prima 
tized antibody, and Ladner et al., U.S. Pat. No. 4,946,778 and 
Bird, R. E. et al., Science, 242: 423-426 (1988)) regarding 
single chain antibodies. 
The agent may be conjugated to a detectable label. A 
detectable label is a moiety, the presence of which can be 
ascertained directly or indirectly. The detectable label may 
be, e. g., a radioisotope, a bioimaging ?uorochrome, a contrast 
agent, or a gaseous agent. The agent may be e.g., a ?uores 
cently labeled CCR3-speci?c antibody or antibody fragment, 
e.g., a CCR3-speci?c Fab or CCR3 speci?c peptide or 
aptamer. The agent may be conjugated to a bioimaging ?uo 
rochrome, e.g., a near infrared dye or semiconductor nanoc 
rystals “quantum dots” and iron oxide nanocrystals. Those of 
ordinary skill in the art will know of suitable labels for bind 
ing to the agents used in the methods described herein, or will 
be able to ascertain such, using routine experimentation. The 
coupling of these labels to the agents used in the methods of 
the invention may be accomplishedusing standard techniques 
well-known to those of ordinary skill in the art. For example, 
nanoparticle probes have been used as labels in biological 
systems and for bioimaging (Akerman et al., Proc Natl Acad 
Sci USA 2002, 99:12617; Santra et al.,Analytical Chemistry, 
2001, 73:4988; Santra et al., Journal ofBiomedical Optics, 
2001, 6:160; Ben-Ari et al., Journal ofthe National Cancer 
Institute, 2003, 95:502; Panyam et al., International Journal 
of Pharmaceutics, 2003, 262:1); diagnostic (Brigger et al., 
Adv Drug Deliv Rev, 2002, 54:631; Alivisatos, Scientific 
American, 2001, 285:66), and therapeutic purposes (Emerich 
et al., Expert Opinion on Biological Therapy 2003, 3:655; 
Douglas et al., Crc Critical Reviews in Therapeutic Drug 
Carrier Systems, 1987, 3:233; Holm et al., Molecular Crys 
tals and Liquid Crystals, 2002, 374:589). Diagnostic neu 
roimaging techniques such as angiography, CT (computed 
tomography) and MRI are well-known and widely used to 
monitor changes in anatomy and disease diagnosis (Hilde 
brandt et al., Clinical Immunology, 2004, 111:210; DZik 
JurasZ et al., British Journal ofRadiology, 2004:77, 296; 
Costouros et al., Journal of Cellular Biochemistry, 2002:72; 
Langer et al., World Journal of Surgery, 2001, 25: 1428; Smith 
et al., Journal ofNeurotrauma, 1995, 12:573; Kreel et al., 
Postgraduate Medical Journal, 1991, 67:334). Contrast 
agents are often administered to patients, to help delineate 
pathological from healthy tissue. Contrast agents for angiog 
raphy and CT scans are radio-opaque, which allow clear 
visualization of the contrast under an X-ray source. Iodinated 
chemical compounds such as iohexyl (also called 
OMNIPAQUETM) and iodixanol (also called VISIPAQUETM) 
are routinely used as X-ray contrast agents. They consist of 
electron dense iodine atoms, which show contrast under an 
X-ray. MRI contrast agents such as Gadoteridol, (Gd-HP 
DO3A, a gadolinium chelate complex, also known as PRO 
HANCETM) and mangafodipir trisodium (a manganese che 
late complex, also known as TESLASCANTM) are usually 
paramagnetic. Both gadolinium and manganese atoms con 
tain unpaired electrons, which account for paramagnetic 
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behavior and resultant MRI contrast. See also U.S. Publica 
tion No. 20070269382 for a description of nanoparticles and 
their use for multifunctional bioimaging. 
Another aspect of this invention is a method for treating 
CNV in a subject in need thereof comprising administering to 
the subject a CCR3 antagonist in an amount suf?cient to 
inhibit progression of CNV. “Treating CNV in a subject” 
includes e.g., stopping, slowing or reversing the progression 
of CNV in the subject. In one aspect of the invention the retina 
of the subject is not invaded by CNV but CNV is detected in 
the choroid, e.g., CCR3 expression is detected in vessels in 
the choroid. The CCR3 antagonist may be, e.g., a CCR3 
neutraliZing antibody or CCR3 neutraliZing antibody frag 
ment or a peptide that competes with a natural ligand for 
binding to CCR3 or a peptide or low molecular weight com 
pound having activity which inhibits binding of CCR3 
ligands to CCR3 on target cells. The CCR3 antagonist may 
also be a peptide that speci?cally binds to CCR3, wherein the 
peptide is conjugated to toxin or cytostatic agent that kills or 
inhibits the growth of cells expressing CCR3. The CCR3 
neutraliZing antibody fragment may be e. g., a CCR3-speci?c 
Fab. The CCR3-speci?c antibody or antibody fragment may 
be conjugated to a compound suitable for bioimaging, e.g., 
bioimaging ?uorochrome such as a near-infrared ?uorophore 
(“NIRF”) or quantum dot. 
A subject in need thereof may be a subject at risk for 
developing or suspected of having choroidal neovasculariza 
tion. The subject may be e. g., a subject at risk for developing 
age related macular degeneration or an individual with RPE 
pigmentary disturbances, multiple subretinal lipoproteina 
ceous deposits or fellow eye involvement with clinically evi 
dent CNV. In one aspect of the invention, the retina of a 
subject at risk for developing or suspected of having choroi 
dal neovascularization is not invaded by CNV. 
In the methods of this invention the agent which speci? 
cally binds to CCR3 or to eotaxin 1, 2 or 3, or the CCR3 
speci?c antagonist may be administered systemically or 
locally. For example, the agent or CCR3-speci?c antagonist 
may be administered intravenously, intrathecally, intraarteri 
ally, intranasally, orally, subcutaneously, intraperitoneally, or 
by local injection or surgical implant in an amount suf?cient 
to detect CCR3 on choriod vessels or to inhibit CNV progres 
sion. 
The invention also relates to a method for evaluating the 
risk of a subject for developing retinal CNV. In one aspect of 
the invention, a subject is assayed for CCR3 expression in 
choroid vessels, wherein expression of CCR3 in choriod ves 
sels is indicative of choridal CNV or an elevated risk for 
developing retinal CNV. In another aspect of this invention, 
the level of CCR3 expression is compared to the expression 
level in the choroid of subjects who are not at risk for devel 
oping or suspected of having choroidal neovascularization 
Also an aspect of this invention is a method for assaying a 
pre-selected agent for inhibition of choroid CNV in a subject 
comprising detecting expression of CCR3 in the choroid of 
the subject by bioimaging before and after treatment with an 
agent and comparing expression levels or localization of 
CCR3 in the choroid before and after treatment, wherein a 
reduction in CCR3 expression in the choroid or a change in 
the localization of CCR3 in the choroid is indicative of inhi 
bition of CNV by the agent. The subject may e.g., have CNV 
in the choroid and/or the retina of the subject may also have 
CNV. 
EXAMPLES 
Methods 
Mouse model of CNV. Laser photocoagulation (OcuLight 
GL, Iridex Corporation) was performed on mouse eyes to 
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induce CNV, and CNV volumes were measured 7 days after 
injury by scanning laser confocal microscope (TCS SP, 
Leica) as previously described (Kleinman, et al., Nature. 452, 
591-597 (2008)). Drug injections. Rat IgG2a neutralizing 
antibody against mouse CCR3 (R&D Systems), control rat 
IgG2a (Serotec), goat neutralizing antibody against mouse 
CCL11 (R&D Systems), goat neutralizing antibody against 
mouse CCL24 (R&D Systems), control goat IgG (Jackson 
Immunoresearch), or (S)-Methyl-2-naphthoylamino-3-(4-ni 
trophenyl)propionate (SB328437; Calbiochem) dissolved in 
DMSO were injected into the vitreous humor using a 
33-gauge double-calibre needle (Ito Corporation) once, 
immediately after laser injury as previously described (Klein 
man, et al., (2008) supra). 
CCR3 bioimaging. F(ab) fragments were created from 
monoclonal IgG2a antibody raised against the extracellular 
domain of murine CCR3 (R&D Systems) and an isotype rat 
IgG2a (R&D Systems) using a commercially available 
papain-based kit (Pierce). Recovered fragments were conju 
gated with quantum dots (Invitrogen, QDot-800) and resus 
pended in sterile PBS. Ccl2_/_><Ccr2_/_ mice were adminis 
tered 100 pg of tagged CCR3 F(ab) or isotype F(ab) via tail 
vein injection after acquiring baseline ?uorescent imaging 
using a Topcon retinal camera (TRC-501X). Serial images 
were then acquired at 1, 4, and 12 h after which eyes were 
harvested and frozen in OCT for immuno?uorescent analy 
ses. Retinal images were analyzed (ImageNet, Topcon) by 
comparison to baseline and ?uorescein angiographic data. 
Hyper?uorescent areas were then cropped, equally thresh 
olded, and pseudocolored (Photoshop CS3, Adobe). Sections 
from QDot-conjugated CCR3 or rat IgG2a isotype F(ab) 
injected animals were ?xed in 4% paraformaldehyde and 
blocked with 5% normal donkey serum/5% goat serum in 
PBS, stained with rat anti-mouse CD31 (BD Biosciences) and 
either rabbit anti-mouse CCR3 (Santa Cruz) or rabbit anti 
Ki67 (Abcam) followed by appropriate ?uorescent secondary 
antibodies (Alexa Fluor 488/594, Invitrogen), and evaluated 
by confocal laser scanning microscopy (Leica SP-5). 
Methods 
Human tissue. Choroidal neovascularization (CNV) tissue 
was excised from patients with age-related macular degen 
eration (AMD) who had no prior treatment for CNV. Retinal 
?brosis tissue was excised from patients with a diagnosis of 
epiretinal membrane formation. Donor eyes from patients 
with atrophic AMD without CNV and patients without AMD 
were obtained from eye banks. Eyes with choroidal mela 
noma were obtained by surgical enucleation. The study fol 
lowed the guidelines of the Declaration of Helsinki. Institu 
tional review boards granted approval for allocation and 
histological analysis of specimens. 
Animals. All animal experiments were in accordance with 
the guidelines of the University of Kentucky IACUC and the 
Association for Research in Vision and Ophthalmology. 
C57BL/6J and KitW'v/KitW'“ mice were purchased from The 
Jackson Laboratory. Ccr3_/_, Cc111_/_, Ccl24_/_, Cc111_/_>< 
Ccl24_/_, and Adbl GATA mice have been previously 
described (Humbles et al., Science. 305, 1776-1779 (2004); 
Pope et al. J. Immunol. 175, 5341-5350 (2005); Humbles et al. 
Proc NazlAcad Sci USA. 99, 1479-1484 (2002); Rothenberg 
et al., J Exp Med. 185, 785-790 (1997)). Ccl2_/_><Ccr2_/_ 
mice were generated by interbreeding “single knockout” 
mice described previously (Ambati et al., Med. 9, 1390-1397 
(2003)). 
Drug injections. Rat IgG2a neutralizing antibody against 
mouse CCR3 (R&D Systems), control rat IgG2a (Serotec), 
goat neutralizing antibody against mouse CCL1 1 (1 pg; R&D 
Systems), goat neutralizing antibody against mouse CCL24 
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(5 pg; R&D Systems), control goat IgG (Jackson Immunore 
search), or (S)-Methyl-2-naphthoylamino-3-(4-nitrophenyl) 
propionate (SB328437; Calbiochem) dissolved in DMSO 
were injected into the vitreous humor of mice using a 
33-gauge double-calibre needle (Ito Corporation) once, 
immediately after laser injury as previously described (Klein 
man, et al., (2008) supra). 
Flow cytometry. Rat antibody against mouse CCR3 
(1:250; Santa Cruz) coupled with PE-donkey antibody 
against rat IgG (1:250; Jackson Immunoresearch) or Alex 
aFluor647-conjugated rat antibody against mouse CCR3 (10 
pg/ml; BD Biosciences) were used to quantify cell surface 
receptor expression on choroidal endothelial cells, de?ned by 
CD31+ VEGFR-2+ expression, gated by FITC-conjugated rat 
antibody against mouse CD31 (20 pg/ml; BD Biosciences) 
and PE-conjugated rat antibody against mouse VEGFR-2 (20 
pg/ml; BD Biosciences). Macrophages, neutrophils, eosino 
phils and mast cells were de?ned as F4/80+CD11c_, Gr-l+ 
F4/80‘, CCR3’”CD3‘CD117””CD49d+ and CCR3i”’CD3_ 
CD117hiCD49d+ cells, respectively. DNA content for cell 
cycle was analyzed after incubation with propidium iodide 
(0.05 mg/ml; Molecular Probes) containing 0.1% Triton 
X-100 and RNase A (0.1 mg/ml; Roche). Samples were ana 
lyzed on a LSRII (Becton Dickinson). 
Immunolabeling. Immuno?uorescent staining was per 
formed with antibodies against human CCR3 (rat mono 
clonal, R&D Systems) or human CD31 (mouse monoclonal, 
Dako) and identi?ed with Alexa 488 (Molecular Probes) or 
Cy3 secondary antibodies (Jackson ImmunoResearch). 
Immunohistochemical staining with the primary antibodies 
speci?c for human eotaxins-1, 2 and 3 (mouse monoclonal, 
R&D Systems) was performed using horseradish peroxidase. 
Laser injured mouse eye sections were stained with antibod 
ies against mouse CCL11 or CCL24 (both R&D Systems) 
along with antibody against mouse CD31 (BD Biosciences) 
and visualized with FITC or Cy3 secondary antibodies. 
Images were obtained using Leica SP5 or Zeiss Axio 
Observer Z1 microscopes. 
Tube formation assay. 96-well plates were coated with 
Growth Factor Reduced Matrigel (BD Biosciences) mixed 
with rat neutralizing antibody against human CCR3 (20 
pg/ml, R&D Systems) or control rat IgG2a (Invitrogen) and 
allowed to solidify in the incubator at 37° C. for 45 min. 
Human choroidal endothelial cells (CECs)44_47 were plated 
on top of the Matrigel at 2.25><104/cm2 in EBM-2 basal media 
(Cambrex) containing 1% PBS with CCR3 antibody or rat 
IgG2a at the above concentrations and allowed to grow over 
night. Tube formation was analyzed by counting the number 
of cell junctions per m2. 
Proliferation assay. Human CECs were synchronized for 
cell cycle state by ?rst cultivating them in EGM2-MV media 
(Lonza) supplemented with 10% FBS (Gibco) to achieve 
complete con?uence and then by overnight serum starvation 
in MCDB131 media (Gibco) with 0.1% FBS. They were 
passaged to 96-well plates at a density of 5,000 cells per well, 
followed by stimulation for 24 h with eotaxin-1, 2 or 3 (10 ng, 
100 ng and 2 pg per ml, respectively; Peprotech) in 
MCDB131 media with 0.1% PBS. After 24 h, cell viability 
was measured with BrdU ELISA (Chemicon) according to 
manufacturer’ s instructions. 
F-actin Polymerization Assay. Human CECs were seeded 
in black-walled 96-well plates and grown to 70-80% con?u 
ence in fully supplemented EGM-2MV. Cultures were serum 
starved overnight in basal media and then stimulated with 
recombinant human eotaxin-1 (10 ng/ml), eotaxin-2 (100 
ng/ml), eotaxin-3 (2 pg/ml) (Peprotech), or vehicle control 
(PBS). At 0, 10, 30, 60, or 120 sec time-points, cells were 
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?xed in 3.7% paraforrnaldehyde for 10 min, washed, perme 
abilized in PBS with 0.1% Triton-X, and then stained with 
rhodamine labelled Phalloidin (1:200, lnvitrogen) per manu 
facturer’s recommendations. Plates were analyzed on a ?uo 
rescent plate reader (Synergy 4, Biotek) followed by ?uores 
cent microscopy (Nikon E800). 
Migration Assay. Eotaxins-l, -2, -3 were reconstituted in 
0.1% bovine serum albumin (BSA) and then mixed with 
Matrigel diluted 1:1 with serum free endothelial basal media 
(EBM-2; Lanza). 500 pl of EBM-2 was added to each well of 
a 24-well plate followed by a 6.5 mm diameter Transwell 
insert (8 pm pores; Corning). Human CECs in EBM-2 were 
prestained witthbrant DiO (lnvitrogen) for 30 min at 370 C. 
and seeded into the inserts at 50,000 cells per 200 pl of serum 
free EBM-2 media. The plates were allowed to incubate for 
16 h at 370 C., 5% C02. The migrated cells were imaged with 
an Olympus CK40 microscope and Olympus DP71 camera. 
Rac-l activation. Human CECs were cultured in EGM-2 
MV containing 5% FBS. Prior to starting the assay, cells were 
serum starved with basal medium (MCDB13 1) supplemented 
with 1% FBS overnight. Cells were stimulated for designated 
times with Eotaxin-l, 2 and 3 (10 ng/ml, 100 ng/ml and 2 
pg/ml respectively). Equal amounts of lysates (500 pg) were 
incubated with GST-Pakl-PBD agarose beads (Upstate) to 
pull-down active GTP-bound Rac-l at 4° C. for 1 h with 
rotation. The samples were subsequently analyzed for bound 
Rac-l by western blot analysis using an anti-Rac-l antibody 
(Upstate). 
Electroretinography. Mice were dark adapted overnight 
and then anesthetized. Both eyes were positioned within a 
ColorBurst Ganzfeld stimulator (Diagnosys). Espion soft 
ware (Diagnosys) was used to program a fully automated 
?ash intensity series from which retinal responses were 
recorded. 
All references cited in this disclosure are incorporated by 
reference to the same extent as if each reference had been 
incorporated by reference in its entirety individually. 
While the invention has been described in detail and with 
reference to speci?c embodiments thereof, it will be apparent 
to one skilled in the art that various variations and modi?ca 
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tions can be made therein without departing from the sprit and 
scope thereof. All such variations and modi?cations are 
intended to be includedwithin the scope of this disclosure and 
the present invention and protected by the following claims. 
We claim: 
1. A method for detecting subclinical choroidal neovascu 
larization (“CNV”) comprising contacting a choroid with an 
agent that speci?cally binds CCR3 and assaying the choroid 
for binding of the agent to vessels in the choroid, wherein 
binding of the agent to vessels in the choroid is indicative of 
subclinical CNV. 
2. The method of claim 1 wherein the agent is a CCR3 
speci?c antibody; a CCR3-speci?c antibody fragment; 
eotaxin 1, eotaxin 2 or eotaxin 3; a fragment of eotaxin 1, 
eotaxin 2 or eotaxin 3 that binds to CCR3; a peptide or 
aptamer that speci?cally binds to CCR3, eotaxin 1, eotaxin 2 
or eotaxin 3; or a CCR3-speci?c small molecule inhibitor. 
3. The method of claim 2 wherein the agent is conjugated to 
a detectable label. 
4. The method of claim 2 wherein the label is a bioimaging 
?uorochrome. 
5. The method of claim 4 wherein the bioimaging ?uoro 
chrome is a near infrared dye or quantum dot. 
6. The method of claim 1 wherein the agent is a detectable 
CCR3-speci?c antibody or antibody fragment. 
7. The method of claim 6 wherein the CCR3-speci?c anti 
body fragment is a CCR3-speci?c Fab. 
8. The method of claim 7 wherein the CCR3-speci?c Fab is 
conjugated to a bioimaging ?uorochrome. 
9. The method of claim 1 wherein the choroid is in or from 
a subject at risk for developing or suspected of having chor 
oidal neovascularization. 
10. The method of claim 9 wherein the subject is a subject 
at risk for developing age-related macular degeneration. 
11. The method of claim 9 wherein the subject is an indi 
vidual with retinal pigmented epithelium (“RPE”) pigmen 
tary disturbances, multiple subretinal lipoproteinaceous 
deposits or fellow eye involvement with clinically evident 
CNV. 
